Earnings ·
Pulse Biosciences reported second quarter 2026 financial results and business updates
PLSEPulse Biosciences, Inc.
Pulse Biosciences reported second quarter 2026 financial results and business updates. The company raised $46.8 million in net proceeds through its at-the-market equity program during the quarter, bringing cash and cash equivalents to $101.6 million as of June 30, 2026. Total revenue was $0.4 million against GAAP costs and expenses of $25.7 million, resulting in a GAAP net loss of $24.7 million. Clinically, the NANOPULSE-AF pivotal study surpassed halfway enrollment with over 82 evaluable patients, targeting completion by early Q4 2026 after protocol amendments expanded the patient pool to 164. The company also advanced its surgical AF ablation and soft tissue programs, including a new partnership for benign thyroid nodule treatment. Pulse Biosciences is a medical device company developing nanosecond pulsed field ablation technology for cardiac and soft tissue treatments.